Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial.

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes ...

Vertex Pharmaceuticals has shared data from the Phase I/II segment of the Phase I/II/III FORWARD-101 trial, evaluating ...

Lundbeck’s Vyepti (eptinezumab) has met both the primary and secondary endpoints in the placebo-controlled Phase IV ...

A report from the CDC across the US has found that ASD rates in children aged between 4-8 years were higher in 2022 than in ...

An expert from a CRO-SMO outlines Japan's advantages as a potential clinical trial site, in terms of services and regulatory ...

MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

Patient-centric approaches such as AI and decentralised trials are improving oncology trial enrolment, but 2025 has given ...

At the 15th Annual Outsourcing in Clinical Trials (OCT) Europe conference, which took place between 29 and 30 April in ...

Ventyx Biosciences has reported encouraging top-line outcomes from its Phase IIa trial of VTX3232 for early-stage Parkinson's ...

Biogen has commenced dosing in the Phase III BRAVE study of omaveloxolone in children of two-< 16 years of age with ...